# Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

> **NCT04906382** · EARLY_PHASE1 · TERMINATED · sponsor: **Floor Backes, MD** · enrollment: 2 (actual)

## Conditions studied

- Lynch Syndrome
- Recurrent Endometrial Carcinoma
- Recurrent Endometrial Clear Cell Adenocarcinoma
- Recurrent Uterine Corpus Carcinosarcoma
- Mismatch Repair Deficiency
- Recurrent Endometrial Cancer
- Metastatic Endometrial Cancer

## Interventions

- **PROCEDURE:** Biopsy
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Tislelizumab

## Key facts

- **NCT ID:** NCT04906382
- **Lead sponsor:** Floor Backes, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Sponsor reorganization
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906382, "Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04906382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*